GUTS (Fractyl Health) Other Current Liabilities: $0.60 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GUTS Fractyl Health Inc GUTS
11 GF Score
Price $0.70
! 2 Warning Signs
View Full Analysis

What is Fractyl Health Other Current Liabilities?

Fractyl Health GUTS +1.15% 11 Other Current Liabilities is $0.60 Mil as of Mar. 2026. GuruFocus rates GUTS with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Fractyl Health's other current liabilities for the quarter that ended in Mar. 2026 was $0.60 Mil.

Fractyl Health's quarterly other current liabilities increased from Sep. 2025 ($0.51 Mil) to Dec. 2025 ($0.96 Mil) but then declined from Dec. 2025 ($0.96 Mil) to Mar. 2026 ($0.60 Mil).

Fractyl Health's annual other current liabilities increased from Dec. 2023 ($0.58 Mil) to Dec. 2024 ($0.83 Mil) and increased from Dec. 2024 ($0.83 Mil) to Dec. 2025 ($0.96 Mil).

Fractyl Health Other Current Liabilities Related Terms

Fractyl Health Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Fractyl Health's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fractyl Health Other Current Liabilities Chart

Fractyl Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial 0.10 0.04 0.58 0.83 0.96

Fractyl Health Quarterly Data
Sep20 Dec20 Jun21 Sep21 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.51 0.51 0.96 0.60
GUTS
11GF Score
Fractyl Health Inc GUTS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fractyl Health Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.60 Mil mean?
Fractyl Health (GUTS) has a Other Current Liabilities of $0.60 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Fractyl Health.
Is Fractyl Health's Other Current Liabilities too high?
Fractyl Health's current Other Current Liabilities is $0.60 Mil. Overall, Fractyl Health has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fractyl Health's Other Current Liabilities compare to ENGN and ANIX?
Fractyl Health's Other Current Liabilities of $0.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Fractyl Health. Fractyl Health's current Other Current Liabilities is $0.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fractyl Health stock overvalued right now?
Fractyl Health (GUTS) has a current Other Current Liabilities of $0.60 Mil. The current Other Current Liabilities is $0.60 Mil. Fractyl Health's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Fractyl Health (GUTS), the current Other Current Liabilities is $0.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fractyl Health Business Description

Address 3 Van de Graaff Drive, Suite 200, Burlington, MA, USA, 01803
Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.
11GF Score

Get the complete analysis for GUTS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.70
Price